Conventional fibrinolytic assays for the evaluation of patients with venous thrombosis: Don't bother

Thrombosis and Haemostasis

Volumn 85, Issue 3, 2001, Pages 377-378

  Bauer, K A ^a  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIGEN; BLOOD CLOTTING FACTOR 5 LEIDEN; FIBRIN; INSULIN; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ASSAY; CIRCADIAN RHYTHM; DEEP VEIN THROMBOSIS; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENZYME ACTIVITY; ENZYME ANALYSIS; FIBRINOGEN DEFECT; FIBRINOLYSIS; GENE MUTATION; HETEROZYGOSITY; HUMAN; IMMUNOCHEMISTRY; MEDICAL DECISION MAKING; NOTE; PRIORITY JOURNAL; PROTEIN S DEFICIENCY; RECURRENT DISEASE; RISK FACTOR; SCREENING TEST; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; VEIN OCCLUSION; VEIN THROMBOSIS;

EID: 0035077396     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615592     Document Type: Note

References (24)

1. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: Low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor
2. The role of the fibrinolytic system in deep venous thrombosis
3. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis
4. Residual plasminogen activator activity after venous stasis as a criterion for hypofibrinolysis: A study in 83 patients with confirmed deep venous thrombosis
5. Elevated plasminogen activator inhibitor (PAI), a cause of thrombophilia? - A study in 203 patients with familial or sporadic venous thrombophilia
6. Hypofibrinolysis in patients with a history of idiopathic deep venous thrombosis and/or pulmonary embolism
7. Regulation of fibrinolysis in the development of atherthrombosis: Role of adipose tissue
8. A family with thromboembolic disease associated with deficient fibrinolytic activity in vessel wall
9. A family with reduced plasminogen activator activity in blood associated with recurrent venous thrombosis
10. Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VIII/von Willebrand factor
11. Association of protein S deficiency with thrombosis in a kindred with elevated levels of plasminogen activator-1
12. Protein S deficiency in a large family with thrombophilia previously characterized as having an inherited fibrinolytic defect
13. Impaired fibrinolytic capacity predisposes for recurrence of venous thrombosis
14. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Duration of Anticoagulation (DURAC) Trial Study Group
15. Thromboembolic disease - Critical evaluation of laboratory investigation
16. Fibrinolytic variables in patients with recurrent venous thrombosis: A prospective cohort study
17. Recurrent deep vein thrombosis and two coagulation factor gene mutations: Quo vadis?
18. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study
19. Mutation in blood coagulation factor V associated with resistance to activated protein C
20. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men
21. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated prothrombin levels and an increase in venous thrombosis
22. Factor XI and protection of the fibrin clot against lysis - A role for the intrinsic pathway of coagulation in fibrinolysis
23. Thrombin-mediated activation of factor XI results in a TAFI (thrombin activatable fibrinolysis inhibitor) dependent inhibition of fibrinolysis
24. High levels of coagulation factor XI as a risk factor for venous thrombosis